Waldenstrom Macroglobulinemia Questions & Answers

1. Kaseb H, Gonzalez-Mosquera LF, Parsi M, Mewawalla P. Lymphoplasmacytic Lymphoma. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. Caers J, Vekemans MC, Bries G, Beel K, Delrieu V, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013 Sep. 45 (5-6):413-22. [QxMD MEDLINE Link].

3. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr. 30 (2):110-5. [QxMD MEDLINE Link].

4. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, et al. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Jan 5. [QxMD MEDLINE Link]. [Full Text].

5. Gertz MA. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017 Feb. 92 (2):209-217. [QxMD MEDLINE Link].

6. Kapoor P, Paludo J, Ansell SM. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Curr Treat Options Oncol. 2016 Mar. 17 (3):16. [QxMD MEDLINE Link].

7. Dimopoulos MA, et al; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2016 Dec 9. [QxMD MEDLINE Link]. [Full Text].

8. Pasricha SR, Juneja SK, Westerman DA, Came NA. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. J Clin Pathol. 2011 Jun. 64(6):520-3. [QxMD MEDLINE Link].

9. Jalali S, Price-Troska T, Paludo J, Villasboas J, Kim HJ, Yang ZZ, et al. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Adv. 2018 Aug 14. 2 (15):1985-1997. [QxMD MEDLINE Link]. [Full Text].

10. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30. 367 (9):826-33. [QxMD MEDLINE Link]. [Full Text].

11. Ogmundsdottir HM, Einarsdottir HK, Steingrimsdottir H, Haraldsdottir V. Familial predisposition to monoclonal gammopathy of unknown significance, Waldenström's macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma. 2009 Mar. 9(1):27-9. [QxMD MEDLINE Link].

12. Genetics Home Reference. MYD88 gene. U.S. National Library of Medicine. Available at https://ghr.nlm.nih.gov/gene/MYD88#conditions. May 12, 2020; Accessed: May 20, 2020.

13. Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019 Dec 5. 134 (23):2022-2035. [QxMD MEDLINE Link]. [Full Text].

14. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Cancer. 2011 Dec 2. [QxMD MEDLINE Link].

15. Kastritis E, Zervas K, Repoussis P, et al. Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma. 2009 Mar. 9(1):50-2. [QxMD MEDLINE Link].

16. Advani P, Paulus A, Ailawadhi S. Updates in prognostication and treatment of Waldenström's macroglobulinemia. Hematol Oncol Stem Cell Ther. 2019 May 28. [QxMD MEDLINE Link]. [Full Text].

17. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 Jun 1. 37 (16):1403-1411. [QxMD MEDLINE Link].

18. Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 Nov. 33 (11):2654-2661. [QxMD MEDLINE Link].

19. Kastritis E, Kyrtsonis MC, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. Am J Hematol. 2011 Jun. 86(6):479-83. [QxMD MEDLINE Link].

20. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19. 123(25):3999-4000. [QxMD MEDLINE Link].

21. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 1. 123(18):2791-6. [QxMD MEDLINE Link].

22. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr. 30(2):211-5. [QxMD MEDLINE Link].

23. Menke MN, Feke GT, McMeel JW, Treon SP. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar. 9(1):100-3. [QxMD MEDLINE Link].

24. D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 Feb 15. [QxMD MEDLINE Link]. [Full Text].

25. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009 Aug. 55(8):1517-22. [QxMD MEDLINE Link].

26. Thomas R, Braschi-Amirfarzan M, Laferriere SL, Jagannathan JP. Imaging of Waldenström Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine. AJR Am J Roentgenol. 2019 Jul 9. 1-9. [QxMD MEDLINE Link].

27. Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014 Mar 13. 123(11):1637-46. [QxMD MEDLINE Link].

28. Poulain S, Ertault M, Leleu X, et al. SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia. Leuk Res. 2009 Sep. 33(9):1204-7. [QxMD MEDLINE Link].

29. Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019 Dec 5. 134 (23):2022-2035. [QxMD MEDLINE Link]. [Full Text].

30. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21. 378 (25):2399-2410. [QxMD MEDLINE Link].

31. Mulcahy N. FDA Approval for Zanubrutinib in Waldenström’s Macroglobulinemia. Medscape Medical News. Available at https://www.medscape.com/viewarticle/958058. September 2, 2021; Accessed: September 3, 2021.

32. [Guideline] Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov. 7 (11):e827-e837. [QxMD MEDLINE Link].

33. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. Br J Haematol. 2018 Aug 6. [QxMD MEDLINE Link].

34. Menke MN, Feke GT, McMeel JW, Treon SP. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Invest Ophthalmol Vis Sci. 2008 Mar. 49(3):1157-60. [QxMD MEDLINE Link]. [Full Text].

35. Treon SP, Hansen M, Branagan AR. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with the clinical response to rituximab in waldenstrom's macroglobulinemia. J Clin Oncol. 2005. 23:474-81.

36. FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma. U.S. Food & Drug Administration. Available at https://wayback.archive-it.org/7993/20170723002608/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm. January 29, 2015; Accessed: August 26, 2018.

37. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 9. 372 (15):1430-40. [QxMD MEDLINE Link]. [Full Text].

38. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2020 Sep 15. JCO2000555. [QxMD MEDLINE Link].

39. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015 Aug 6. 373 (6):584-6. [QxMD MEDLINE Link]. [Full Text].

40. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 Jul 25. JCO2018786426. [QxMD MEDLINE Link].

41. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022 Jan 1. 40 (1):52-62. [QxMD MEDLINE Link].

42. Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 Oct 29. 136 (18):2038-2050. [QxMD MEDLINE Link]. [Full Text].

43. Dhodapkar MV, Jacobson JL, Gertz MA. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001. 98:41-48.

44. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20. 31 (3):301-7. [QxMD MEDLINE Link]. [Full Text].

45. Dimopoulos MA, Kastritis E, Roussou M, et al. Rituximab-based treatments in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar. 9(1):59-61. [QxMD MEDLINE Link].

46. Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 Jan 26. 129 (4):456-459. [QxMD MEDLINE Link].

47. Tedeschi A, Alamos SM, Ricci F, Greco A, Morra E. Fludarabine-based combination therapies for Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar. 9(1):67-70. [QxMD MEDLINE Link].

48. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroblobulinemia. Clin Lymphoma. 2005. 4:273-7.

49. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2011 Jul 5. [QxMD MEDLINE Link].

50. Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol. 2003 Apr. 30(2):270-4. [QxMD MEDLINE Link].

51. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10. 28(8):1422-8. [QxMD MEDLINE Link]. [Full Text].

52. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10. 28(8):1408-14. [QxMD MEDLINE Link]. [Full Text].

53. Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14. 118(2):276-81. [QxMD MEDLINE Link]. [Full Text].

54. Leblond V, Levy V, Maloisel F. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001. 98:2640-4.

55. Treon SP, Morel P, Leblond V, Fermand JP. Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar. 5(4):215-6. [QxMD MEDLINE Link].

56. Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol. 1999 Jun. 105(4):993-6. [QxMD MEDLINE Link].

57. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, et al. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 Jan. 23 (1):60-66. [QxMD MEDLINE Link].

58. [Guideline] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf. Version 2.2022 — December 7, 2021; Accessed: February 3, 2022.

59. [Guideline] Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, et al. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1. 29 (Supplement_4):iv270. [QxMD MEDLINE Link]. [Full Text].

60. [Guideline] Pratt G, El-Sharkawi D, Kothari J, D'Sa S, Auer R, McCarthy H, et al. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022 Jan 12. [QxMD MEDLINE Link]. [Full Text].

61. Varghese AM, Rawstron AC, Ashcroft AJ, Moreton P, Owen RG. Assessment of bone marrow response in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar. 9(1):53-5. [QxMD MEDLINE Link].

62. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom's macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar. 9(1):71-3. [QxMD MEDLINE Link].

Karen Seiter, MD Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College

Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology

Disclosure: Received honoraria from Novartis for speaking and teaching; Received consulting fee from Novartis for speaking and teaching; Received honoraria from Celgene for speaking and teaching.

Doris Ponce, MD Fellow, Department of Hematology/Oncology, New York Medical College

Doris Ponce, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Hematology, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Wendy Hu, MD Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center

Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Hematology, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Koyamangalath Krishnan, MD, FRCP, FACP Paul Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine and Chief of Hematology-Oncology, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, and Royal College of Physicians

Disclosure: Nothing to disclose.

Vijay Ramu, MBBS Staff Physician, Department of Internal Medicine, East Tennessee State University

Vijay Ramu, MBBS is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Harsha Vyas, MD Fellow, Section of Hematology and Oncology, Wake Forest University School of Medicine

Harsha Vyas, MD is a member of the following medical societies: American College of Physicians, American Society of Clinical Oncology, and American Society of Hematology

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article